CN105250613A - Medicine for treating chronic obstructive pulmonary disease in stable phase - Google Patents
Medicine for treating chronic obstructive pulmonary disease in stable phase Download PDFInfo
- Publication number
- CN105250613A CN105250613A CN201510803844.4A CN201510803844A CN105250613A CN 105250613 A CN105250613 A CN 105250613A CN 201510803844 A CN201510803844 A CN 201510803844A CN 105250613 A CN105250613 A CN 105250613A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- chronic obstructive
- semen
- obstructive pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating chronic obstructive pulmonary disease in the stable phase. The medicine is characterized by being prepared from the following medicinal raw materials: pawpaws, prinsepia uniflora batal, semen euryales, pyrola rotundifolia, cipadessa baccifera, tricyrtis root, pseudodrynaria coronans, cinnamomum camphora, parmelia tinctourium, semen aesculi, solanum lyratum thunb and semen lini. Clinical experiments prove that the medicine has the characteristics of good curative effect and relatively high safety when being used for treating chronic obstructive pulmonary disease, and is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Patients With Stable Copd treatment inhalable aerosol drug.
Background technology
Chronic obstructive pulmonary disease and chronic obstructive pulmonary disease (chronicobstructivepulmonarydiseases, COPD), with not exclusively reversible flow limitation for feature.In chronic obstructive pulmonary disease, modal symptom is cough, expectoration, and the cough increased the weight of for a long time, repeatedly, is gradually the outstanding behaviours of primary disease.The chronic obstructive pulmonary disease course of disease can be divided into Acute Exacerbation Period and stable phase.Chronic obstructive pulmonary disease Acute Exacerbation Period occurs together the inflammation performances such as heat more, needs hospitalization, and stable phase is then general only with cough, expectoration, the symptom such as to breathe hard, and there is no inflammatory reaction.The clinical process for COPD at present, need treat respectively according to the course of disease, Acute Exacerbation Period anti-inflammatory treatment is effective and necessary, and stable phase is many without inflammation, but clinically often can not distinguish with chronic bronchitis, still treat with a large amount of anti-inflammatory drug, Chinese medicine is also like this, still use a large amount of heat-clearing and toxic substances removing medicines at stable phase, of a specified duration causes abuse of antibiotics or cold and cool impairing the lung.Or think that stable phase should correction simply, reinforcing spleen and kidney, ignore the correction of cough symptom.
Pathological study in recent years shows, respiratory secretions increases, mucilage secretion disorder and removing obstacles are the inherent mechanisms of COPD cough morbidity, in order to solve the problem, have clinical opinion postoperative use oxygen nebulization ambroxol to suck at present, its pharmacological action is into the secretion of pulmonary surfactant and airway fluids secretion, the mucopolysaccharide azelon of apoplexy due to phlegm is ruptured, promotes that glutinous expectorant dissolves, significantly reduce expectorant viscosity, strengthen bronchial mucosa ciliary movement, promote that sputum is discharged.But because ambroxol is only apophlegmatisant, there is no antitussive effect, patient can not obtain curative effect in a short time, cause treatment cold feet or oneself blindly seek antitussive medicine, and use antitussive medicine, then bronchial secretion can be caused to be detained because of suppression coughre flex, cause pulmonary ventilation not enough, even segmental atelectasis, and then there is pulmonary infection.Therefore, need to seek one and both can alleviate COPD stable phase cough symptom, reduce patient suffering, the medicine of incidence of pulmonary infection can be increased again.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of Patients With Stable Copd medicine for treatment thing, both can alleviate COPD stable phase cough symptom, and reduce patient suffering, can increase incidence of pulmonary infection again.
The technical scheme that the present invention solves its technical problem is: a kind of Patients With Stable Copd medicine for treatment thing, it is characterized in that being prepared from by the crude drug of following weight proportion: Fructus Chaenomelis 10 ~ 30 parts, Rui core 3 ~ 12 parts, sub-sieve Chinese toon 3 ~ 12 parts, Radix Tricyrtidis pilosae 12 ~ 20 parts, precipice Rhizoma Zingiberis Recens 12 ~ 20 parts, Herba pyrolae japonicae 12 ~ 20 parts, Radix Cinnamomi porrecti 12 ~ 20 parts, Parmelia saxatilis Ach. 10 ~ 25 parts, Semen Aesculi 12 ~ 20 parts, 12 ~ 20 parts, Gorgon fruit, Semen Lini 3 ~ 12 parts, Herba Solani Lyrati 1 ~ 5 part.
Wherein said: Fructus Chaenomelis is rosaceous plant chaenomeles lagenaria Chaenomelesspeciosa(Sweet) the dry almost ripe fruit of Nakai.Nature and flavor acid, temperature.Return liver, spleen channel.Function cures mainly: suppressing the hyperactive liver relaxing muscles and tendons, stomach function regulating removing dampness.For arthralgia chiefly caused by damp pathogen contracture, the heavy pain of waist knee joint acid, convulsion of vomiting and diarrhoea, beriberi edema.
Rui core is the drying and ripening pit of rosaceous plant Rui core PrinsepiaunifloraBatal. or tingia Folium Prinsepiae Utilis PrinsepiaunifloraBatal.var.serrataRehd..Nature and flavor are sweet, are slightly cold.Return Liver Channel.Function cures mainly: nourishing the liver to improve visual acuity, wind-dispelling heat-dissipating.For conjunctival congestion and swelling pain, red and fester on the palpebral margin, the dark photophobia of order.
Sub-sieve Chinese toon, is Meliaceae sub-sieve Chinese toon CipadessabacciferaMiq., is used as medicine with root, leaf.Nature and flavor are bitter, cool.Function cures mainly: dispelling wind to relieve the exterior syndrome, preventing the attack (or recurrence) of malaria.Cure mainly malaria.
Radix Tricyrtidis pilosae is the root of liliaceous plant pubescence Herba Tricyrtidis macropodae.Cure mainly traumatic injury.
Precipice Rhizoma Zingiberis Recens is fern Polypodiaceae precipice ginger precipice Rhizoma Zingiberis Recens Pseudodrynariacoronans(Wall.) Ching, is used as medicine with root stock.Nature and flavor are bitter, micro-puckery, temperature.Function cures mainly: expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral.
Herba pyrolae japonicae is the dry herb of Pyrolaceae plant Herba pyrolae japonicae PyrolacallianthaH.Andres or ovum leaf Herba pyrolae japonicae PyroladecorataH.Andres; Nature and flavor are sweet, bitter, temperature; Return liver, kidney channel; Merit can tonify deficiency, kidney tonifying, expelling wind and removing dampness, promoting blood flow to regulate menstruation.
Radix Cinnamomi porrecti, is the aiphyllium of canella Camphor tree, uses its branch and leaf; Nature and flavor are micro-pungent, temperature; Merit can warming middle-JIAO to relieve pain, ward off dirty and in, expelling wind and removing dampness.
Parmelia saxatilis Ach., clock emulsion Stakactite dropstone falls apart and spatters as flower person.Nature and flavor are sweet; Temperature; Nontoxic.Function cures mainly: the kidney warming; Bone strengthening; Supporing yang.Main muscles and bones flaccidity is soft; Waist foot cold type of pain; Impotence and premature ejaculation.
Semen Aesculi is Hippocastanaceae plant Aesculus chinensis Bunge AesculuschinensisBge., Radix Aesculi AesculuschinensisBge.var.chekiangensis(HuetFang) dry mature seed of Fang or Aesculus AesculuswilsoniiRehd..Nature and flavor are sweet, temperature.Return liver, stomach warp.Regulating the flow of QI to ease the stomach, and stomach and alleviating pain.
Gorgon fruit is the dry mature kernal of nymphaeaceae plant Gorgon euryale EuryaleferoxSalisb..Nature and flavor are sweet, puckery, flat.Gui Jing returns spleen, kidney channel.Function cures mainly: supplementing the kidney to control the nocturnal, spleen reinforcing antidiarrheal, damp eliminating leukorrhagia stopping.
Semen Lini is the dry mature seed of flax family (Linaceae) linum Caulis et Folium Lini LinumusitatissimumL..Nature and flavor are sweet, tepor.Function cures mainly: loosening bowel to relieve constipation, nourishing blood to expel wind.For dryness of the intestine constipation; Old man's xerosis cutis Scaling, allergic dermatitis, skin pruritus; Skin infection eczema.
Herba Solani Lyrati is the herb of plant of Solanaceae Herba Solani Lyrati SolanumlyratumThunb..Sweet in the mouth; Bitter; Cold in nature.Return liver; Gallbladder; Kidney channel.Merit can clearing away heat-damp and promoting diuresis; Removing toxic substances and promoting subsidence of swelling.
In prior art, if COPD uses antitussive medicine, then bronchial secretion can be caused to be detained because of suppression coughre flex, cause pulmonary ventilation not enough, and then pulmonary infection occurs.But patient frequently cough can have a strong impact on minimal invasive treatment and rehabilitation.Antitussive and pulmonary infection complication become a pair implacable contradiction.
Compared with prior art, the present invention has following characteristics:
1, this prescription does not use antitussive medicine, but reaches the generation of minimizing respiratory mucus by evacuation aqueous vapor, tracking lung network, thus reduces the generation of irritable cough;
2, side in Fructus Chaenomelis, Rui core for core, described Fructus Chaenomelis, Rui core are used for Liver Channel disease originally, but inventor's clinical practice Fructus Chaenomelis, this medicine of Rui core then can reduce because mucus stimulates the cough caused to carrying out Neulized inhalation, its mechanism is relevant to dispelling wind aproll, and zoopery also confirms, Fructus Chaenomelis, Rui core 2:1 mixing water decocting liquid Neulized inhalation, can reduce the expression of rat model air flue mucin, MUC5AC albumen effectively;
3, sub-sieve Chinese toon can strengthen the evacuation effect of Rui core, and its intensity is apparently higher than other diaphoretic medicine; Radix Tricyrtidis pilosae, precipice Rhizoma Zingiberis Recens can lead to lung network, in order to reduce airway resistance; Three coordinates tracking lung network;
4, Semen Lini can the excessive aproll band of gas of antagonism come impairment of body fluid;
5, Herba pyrolae japonicae and Radix Cinnamomi porrecti, means incubation yang-energy, and gas moves with sun, and helps Fructus Chaenomelis to disperse aqueous vapor; And Herba pyrolae japonicae water extract can suppress the generation of skin-sensitizing antibodies in mice serum and house mouse spleen hemolytic cell, alleviate formula totally for the stimulation of airway mucus;
6, Semen Aesculi, Parmelia saxatilis Ach. collocation have the function of therapeutic method to keep the adverse QI flowing downwards improving inspiration by invigorating kidney-QI;
7, getting Herba Solani Lyrati in a small amount, is the meaning of using corrigent, the raw endogenous dryness to prevent warm drugs thing too.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Fructus Chaenomelis 20g, Rui core 12g, sub-sieve Chinese toon 12g, Radix Tricyrtidis pilosae 15g, precipice Rhizoma Zingiberis Recens 15g, Herba pyrolae japonicae 15g, Radix Cinnamomi porrecti 15g, Parmelia saxatilis Ach. 20g, Semen Aesculi 15g, Gorgon fruit 15g, Semen Lini 12g, Herba Solani Lyrati 2g.
The preparation method of embodiment 1 is: Fructus Chaenomelis, Herba pyrolae japonicae, Rui core, Gorgon fruit, sub-sieve Chinese toon, Radix Tricyrtidis pilosae, precipice Rhizoma Zingiberis Recens, Radix Cinnamomi porrecti, Parmelia saxatilis Ach., Semen Aesculi, Herba Solani Lyrati, Semen Lini mixing and water adding are decocted, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges, use two layers of filtered through gauze again, gained filtrate 60 DEG C ~ 70 DEG C is concentrated into density 1.15, divide after concentrated solution cooling and add 95% ethanol 3 times, solution ethanol concentration is made to reach 75%, airtight standing 48h, filter, filtrate removing ethanol, uses G
4sintered glass funnel filter is to clear and bright, and 100 DEG C, sterilizing 30min, preserves.
Embodiment 2, crude drug weight proportion: Fructus Chaenomelis 10 parts, Rui core 3 parts, sub-sieve Chinese toon 3 parts, Radix Tricyrtidis pilosae 12 parts, precipice Rhizoma Zingiberis Recens 12 parts, Herba pyrolae japonicae 12 parts, Radix Cinnamomi porrecti 12 parts, Parmelia saxatilis Ach. 10 parts, Semen Aesculi 12 parts, 12 parts, Gorgon fruit, Semen Lini 3 parts, Herba Solani Lyrati 1 part.
Embodiment 3, crude drug weight proportion: Fructus Chaenomelis 20 parts, Rui core 12 parts, sub-sieve Chinese toon 12 parts, Radix Tricyrtidis pilosae 15 parts, precipice Rhizoma Zingiberis Recens 15 parts, Herba pyrolae japonicae 15 parts, Radix Cinnamomi porrecti 15 parts, Parmelia saxatilis Ach. 20 parts, Semen Aesculi 15 parts, 15 parts, Gorgon fruit, Semen Lini 12 parts, Herba Solani Lyrati 2 parts.
Embodiment 4, crude drug weight proportion: Fructus Chaenomelis 30 parts, Rui core 12 parts, sub-sieve Chinese toon 12 parts, Radix Tricyrtidis pilosae 20 parts, precipice Rhizoma Zingiberis Recens 20 parts, Herba pyrolae japonicae 20 parts, Radix Cinnamomi porrecti 20 parts, Parmelia saxatilis Ach. 25 parts, Semen Aesculi 20 parts, 20 parts, Gorgon fruit, Semen Lini 12 parts, Herba Solani Lyrati 5 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) Fructus Chaenomelis, Rui core, sub-sieve Chinese toon, Radix Cinnamomi porrecti, precipice Rhizoma Zingiberis Recens, Semen Aesculi, Herba Solani Lyrati, Semen Lini coarse powder are extracted volatile oil with vapor distillation respectively, obtain Mixed chaotic sequences and medicinal residues are for subsequent use;
(2) by gained medicinal residues mixing in Herba pyrolae japonicae, Radix Tricyrtidis pilosae, Gorgon fruit, Parmelia saxatilis Ach. and step 1, add 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, leave standstill after filtered through gauze; Then in decocting liquid, add the ethanol of 95% of 3 ~ 4 times of medicinal liquids, airtight standing 48h, filter, through microporous membrane ultrafiltration after filtrate removing ethanol, filtrate concentrate drying, draws just material;
(3) sprayed into by gained volatile oil in step 1 during step 2 gained just expects, mixing, after pulverizing 100 mesh sieves, sterilizing formed.
The efficient combination of said medicine, coordinates mutually, effectively reach the effect played Patients With Stable Copd treatment, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1.1.1 case selection: patient 100 example that in March, 2011 ~ 2015 are diagnosed as stable phase of chronic obstructive pulmonary disease year March, outpatient clinic main suit is cough, wherein male patient is 81 examples, women's sufferer is 19 examples, age is between 43 ~ 85 years old, mean age is 62.4 years old, the course of disease 3 ~ 24 years, average out to 16.8.And get rid of the patient being associated with pulmonary infection.
1.1.2 divide into groups: be divided into matched group 37 example, liquid group 31 example and powder group 32 example.Compare in sex, age, severity Scaling, cough integration etc. before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 inhalable aerosol drug is selected: matched group adopts Mucosolvan injection, and 15mg is each; Liquid group is with the embodiment of the present invention 1 gained Neulized inhalation liquid, and each using dosage is equivalent to crude drug amount 40g; Powder group is with gained sterile powder in the embodiment of the present invention 3, and each using dosage is equivalent to crude drug amount 40g.
1.2.2 aerosol inhalation method: three groups of patients all adopt Oxygen atomizing inhalation to treat 14d: by medicine physiological saline solution and standardize solution is 20ml, oxygen flow 6 ~ 8L/min, treats 1 every day, each 20min.As occurred together pulmonary infection in all patient treatments, then stop this therapeutic scheme, transfer anti-infective therapy to.
1.2.3 observation index: the course for the treatment of performance, treatment before and after symptom, sign, a situation arises and medication related reactions for pulmonary infection.Symptom standard of comparison is that " cough integration " ((coughscore), standards of grading are comply with " 2013MIMS respiratory system disease guide ".
1.2.4 clinical efficacy judges: with reference to " new Chinese medicine guideline of clinical investigations ", clinic control: cough, cough up phlegm, the transference cure such as asthma and drug withdrawal do not recur in 2 weeks; Effective: to cough, cough up phlegm, the transference cure such as asthma, but recurrence in drug withdrawal 2 weeks; Take a turn for the better: cough, cough up phlegm, the symptom such as asthma takes a turn for the better to some extent; Invalid: to cough, cough up phlegm, the symptom such as asthma is not improved or occurs pulmonary infection.
1.2.5 statistical analysis: SPSS18.0 carries out statistical analysis.Measurement data t checks, enumeration data χ
2inspection.
2 results.
2.1 3 groups of incidence of pulmonary infection and treatment completion rate compare: the pulmonary infection in three groups of patient treatment procedure a situation arises be respectively matched group 3 example, liquid group 1 example, powder group 1 example, simple atomization inspiration treatment plan is interrupted after pulmonary infection occurs, transfer anti-infective therapy to, compare between the incidence of pulmonary infection group of three groups, no significant difference (P>0.05).Three groups of patients complete case and are respectively matched group 34 example, liquid group 31 example, powder group 30 example, and treatment completion rate compares, no significant difference (P>0.05).Result shows, liquid group, powder composing prescription case can not increase incidence of pulmonary infection.
2.1 3 groups complete case cough integral contrast: use the cough table of integrals to complete case status of cough to three groups and mark, see the following form,
| Group | Number of cases | Before treatment | After treatment |
| Matched group | 34 | 4.82±1.04 | 3.19±1.26 |
| Liquid group | 30 | 4.74±1.02 | 1.74±1.05 |
| Powder group | 31 | 4.80±1.26 | 1.81±1.17 |
Result shows, cough integration after three groups of treatments has obvious decline (P<0.05) before all comparatively treating, between group, result shows, liquid group, powder group cough alleviation situation is all significantly better than matched group, and difference has statistical significance (P<0.05).
2.1 3 groups complete case Clinical efficacy comparison: see the following form,
| Group | Number of cases | Clinic control | Effective | Take a turn for the better | Invalid | Total effective rate |
| Matched group | 34 | 7 | 14 | 5 | 8 | 76.47% |
| Liquid group | 30 | 15 | 6 | 8 | 1 | 96.67% |
| Powder group | 31 | 17 | 6 | 7 | 1 | 96.77% |
After treatment 14d, the total effective rate of liquid group, powder group is apparently higher than matched group (χ
2=5.37, P<0.05; χ
2=5.60, P<0.05).Clinic control rate is respectively matched group 20.59%, liquid group 50.00%, powder group 54.84%, compares between group, and difference has statistical significance (χ
2=6.11, P<0.05; χ
2=8.16, P<0.01).Proved invents the beneficial effect that medicine that two kinds of embodiments obtain has good effect, not easily recurs.
2.2 untoward reaction and toleration: during medication and after drug withdrawal, three groups of patient temperatures, breathing, blood pressure, pulse ratio comparatively there was no significant difference (P > 0.05), also all occur without the obvious heart, liver, kidney untoward reaction and symptoms of asthma.
3. conclusion.
This result of study shows, use the beneficial effect that liquid group of the present invention and powder group have good effect, not easily recur, can obvious relieving cough symptom, and have no adverse reaction, illustrate that medicine prepared by the inventive method has the advantage that curative effect is affirmed, safety is high in the cough for the treatment of chronic obstructive pulmonary disease.
Claims (1)
1. a Patients With Stable Copd medicine for treatment thing, is characterized in that being prepared from by the crude drug of following weight proportion: Fructus Chaenomelis 10 ~ 30 parts, Rui core 3 ~ 12 parts, sub-sieve Chinese toon 3 ~ 12 parts, Radix Tricyrtidis pilosae 12 ~ 20 parts, precipice Rhizoma Zingiberis Recens 12 ~ 20 parts, Herba pyrolae japonicae 12 ~ 20 parts, Radix Cinnamomi porrecti 12 ~ 20 parts, Parmelia saxatilis Ach. 10 ~ 25 parts, Semen Aesculi 12 ~ 20 parts, 12 ~ 20 parts, Gorgon fruit, Semen Lini 3 ~ 12 parts, Herba Solani Lyrati 1 ~ 5 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510803844.4A CN105250613A (en) | 2015-11-20 | 2015-11-20 | Medicine for treating chronic obstructive pulmonary disease in stable phase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510803844.4A CN105250613A (en) | 2015-11-20 | 2015-11-20 | Medicine for treating chronic obstructive pulmonary disease in stable phase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250613A true CN105250613A (en) | 2016-01-20 |
Family
ID=55090741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510803844.4A Pending CN105250613A (en) | 2015-11-20 | 2015-11-20 | Medicine for treating chronic obstructive pulmonary disease in stable phase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250613A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946958A (en) * | 2020-01-10 | 2020-04-03 | 江西轩豪中药饮片有限公司 | Traditional Chinese medicine component for treating chronic obstructive pulmonary disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520694A (en) * | 2013-10-25 | 2014-01-22 | 梁轶聪 | Traditional Chinese medicine composition capable of treating chronic obstructive pulmonary disease in stabilization period and preparation method of composition |
| CN104983942A (en) * | 2015-08-13 | 2015-10-21 | 高秀婷 | Ventilating lung qi capsule and preparation method thereof |
-
2015
- 2015-11-20 CN CN201510803844.4A patent/CN105250613A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520694A (en) * | 2013-10-25 | 2014-01-22 | 梁轶聪 | Traditional Chinese medicine composition capable of treating chronic obstructive pulmonary disease in stabilization period and preparation method of composition |
| CN104983942A (en) * | 2015-08-13 | 2015-10-21 | 高秀婷 | Ventilating lung qi capsule and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 杨淑艳等: "中药用于慢性阻塞性肺疾病的研究进展", 《中国药房》 * |
| 段富津: "《方剂学》", 30 June 1995, 上海科学技术出版社 * |
| 白晓旭: "慢性阻塞性肺疾病的肺络癥、瘕、聚、散理论", 《中医杂志》 * |
| 谢宗万等: "《全国中草药汇编》", 31 October 1996, 人民卫生出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946958A (en) * | 2020-01-10 | 2020-04-03 | 江西轩豪中药饮片有限公司 | Traditional Chinese medicine component for treating chronic obstructive pulmonary disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107050338A (en) | Chinese medicine composition and preparation method for treating chronic pharyngitis | |
| CN103720839A (en) | Traditional Chinese medicine for treating knee osteoarthritis | |
| CN103182064A (en) | Medicine for treating cough due to wind-cold evil and preparation method thereof | |
| CN104383445A (en) | Traumatic injury analgesic | |
| CN104042713B (en) | A kind of Chinese medicine composition for the treatment of bronchial asthma | |
| CN101332268B (en) | Medicine for treating rhinitis, sinusitis | |
| CN102772663A (en) | Orally-taken medicine for preventing and treating infantile asthma and preparation method thereof | |
| CN102188568B (en) | Externally applied traditional Chinese medicine powder for treating cold | |
| CN104721665A (en) | Traditional Chinese medicine composition for treating cough and preparation method thereof | |
| CN104288477A (en) | Traditional Chinese medicine preparation curing infantile asthma | |
| CN105250613A (en) | Medicine for treating chronic obstructive pulmonary disease in stable phase | |
| CN105395782A (en) | Preparation method of aerosol inhalation medicine for treating chronic obstructive pulmonary disease | |
| CN101693095B (en) | Traditional Chinese medicine preparation for treating cirrhosis and liver ascites | |
| CN105412826A (en) | Pharmaceutical composition for treating bronchialasthma and application thereof | |
| CN101229338B (en) | Heat cough oral liquid | |
| CN105250614A (en) | Method for preparing throat coughing atomization inhalation powder | |
| CN105311415A (en) | General-anesthesia-operation perioperative period atomization inhaling liquid | |
| CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
| CN105362708A (en) | Preparation method of aerosol inhalation medicine used in general anesthesia perioperative period | |
| CN102614479A (en) | Traditional Chinese medicine lotion preparation method for curing kidney-yang deficiency ecthyma | |
| CN105288217A (en) | Drug for comprehensive intervention after cardiothoracic surgery | |
| CN105288216A (en) | Preparation method of atomized inhaling liquid used after cardiac surgery | |
| CN104435636B (en) | A kind of Chinese medicine composition for preventing paracmasis chronic bronchitis to recur | |
| CN105267578A (en) | Atomized liquid for treating laryngeal cough | |
| CN104998106A (en) | Traditional Chinese medicine composition for treating allergic rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160120 |